These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 19084086

  • 21. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RY, Tjia S, Theriault L, Langer A, Leiter LA, Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Investigators.
    Am J Cardiol; 2009 Sep 15; 104(6):798-804. PubMed ID: 19733714
    [Abstract] [Full Text] [Related]

  • 22. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia.
    Ali YS, Linton MF, Fazio S.
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr 15; 15(2):142-6. PubMed ID: 18316949
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V.
    Vnitr Lek; 2011 Mar 15; 57(3):313-6. PubMed ID: 21495414
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr 15; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.
    Eur J Intern Med; 2009 Mar 15; 20(2):197-200. PubMed ID: 19327612
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome.
    Mehta A.
    Postgrad Med; 2010 May 15; 122(3):61-70. PubMed ID: 20463415
    [Abstract] [Full Text] [Related]

  • 40. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein.
    Backes JM, Gibson CA.
    Ann Pharmacother; 2005 Mar 15; 39(3):523-6. PubMed ID: 15671087
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.